These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 16563673)

  • 21. Analysis of nano drug carriers towards optimum release rate.
    Ng EY; Ng WK
    J Med Eng Technol; 2007; 31(4):243-52. PubMed ID: 17566928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug release from lipid matrices. Part II. Influence of formulation factors on the release of slightly soluble drug.
    Ozdemir N; Ozates B
    Acta Pol Pharm; 1996; 53(2):107-10. PubMed ID: 8960285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization and in vivo evaluation of an oral dual controlled-release tablet dosage form of insulin and duck ovomucoid.
    Agarwal V; Nazzal S; Khan MA
    Pharm Dev Technol; 2008; 13(4):291-8. PubMed ID: 18618331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preparation and in vitro-in vivo evaluation of Witepsol H35 based self-nanoemulsifying drug delivery systems (SNEDDS) of coenzyme Q(10).
    Nepal PR; Han HK; Choi HK
    Eur J Pharm Sci; 2010 Feb; 39(4):224-32. PubMed ID: 20035865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response surface methodology for the optimization of ubiquinone self-nanoemulsified drug delivery system.
    Nazzal S; Khan MA
    AAPS PharmSciTech; 2002; 3(1):E3. PubMed ID: 12916956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formulation and evaluation of mucoadhesive dosage form containing rosiglitazone maleate.
    Krishna SS; Ray S; Thakur RS
    Pak J Pharm Sci; 2006 Jul; 19(3):208-13. PubMed ID: 16935828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Optimization of formulation of Fufang Danshen immediate release tablet by colligation score].
    Hu RF; Zhu JB; Peng DY; Tang JH; Zhou A
    Zhongguo Zhong Yao Za Zhi; 2006 Mar; 31(5):380-2. PubMed ID: 16711419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55.
    Sauer D; Zheng W; Coots LB; McGinity JW
    Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study on index for formulation optimization of sustained or controlled released dosage forms].
    Hong YL; Feng Y; Xu DS
    Zhongguo Zhong Yao Za Zhi; 2006 Jan; 31(1):15-7. PubMed ID: 16548158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solid lipid extrusion of sustained release dosage forms.
    Reitz C; Kleinebudde P
    Eur J Pharm Biopharm; 2007 Sep; 67(2):440-8. PubMed ID: 17481868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of poorly compactable drug tablets manufactured by direct compression using the mixture experimental design.
    Martinello T; Kaneko TM; Velasco MV; Taqueda ME; Consiglieri VO
    Int J Pharm; 2006 Sep; 322(1-2):87-95. PubMed ID: 16806756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-amylose sodium carboxymethyl starch matrices for oral, sustained drug-release: formulation aspects and in vitro drug-release evaluation.
    Brouillet F; Bataille B; Cartilier L
    Int J Pharm; 2008 May; 356(1-2):52-60. PubMed ID: 18280069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Floating hot-melt extruded tablets for gastroretentive controlled drug release system.
    Fukuda M; Peppas NA; McGinity JW
    J Control Release; 2006 Oct; 115(2):121-9. PubMed ID: 16959356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral matrix tablet formulations for concomitant controlled release of anti-tubercular drugs: design and in vitro evaluations.
    Hiremath PS; Saha RN
    Int J Pharm; 2008 Oct; 362(1-2):118-25. PubMed ID: 18640251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formulation and optimization of controlled release mucoadhesive tablets of atenolol using response surface methodology.
    Singh B; Chakkal SK; Ahuja N
    AAPS PharmSciTech; 2006 Jan; 7(1):E3. PubMed ID: 16584161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formulation of a extended release tablet containing dexibuprofen.
    Yi HG; Chi MH; Kim YI; Woo JS; Park ES
    Arch Pharm Res; 2008 Dec; 31(12):1637-43. PubMed ID: 19099235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards controlled release of BDNF--manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain.
    Koennings S; Sapin A; Blunk T; Menei P; Goepferich A
    J Control Release; 2007 Jun; 119(2):163-72. PubMed ID: 17428570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compatibility studies of promethazine hydrochloride with tablet excipients by means of thermal and non-thermal methods.
    Thumma S; Repka MA
    Pharmazie; 2009 Mar; 64(3):183-9. PubMed ID: 19348341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proniosomal oral tablets for controlled delivery and enhanced pharmacokinetic properties of acemetacin.
    Shehata TM; Abdallah MH; Ibrahim MM
    AAPS PharmSciTech; 2015 Apr; 16(2):375-83. PubMed ID: 25319057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.